Answers are grounded in this paper and cite their sources.
Bardoxolone methyl was associated with improvement in the estimated GFR in patients with advanced CKD and type 2 diabetes at 24 weeks. The improvement persisted at 52 weeks, suggesting that bardoxolone methyl may have promise for the treatment of CKD. (Funded by Reata Pharmaceuticals; BEAM ClinicalTrials.gov number, NCT00811889.).
No takes yet. Share an insight, caveat, or question.
Pérgola et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: